Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dexmethylphenidate
2. Focalin
3. Focalin Xr
4. Hydrochloride, Dexmethylphenidate
5. Xr, Focalin
1. Dexmethylphenidate Hcl
2. Focalin
3. D-threo-methylphenidate Hydrochloride
4. 19262-68-1
5. Focalin Xr
6. 23655-65-4
7. Metadate Cd
8. Metadate Er
9. Equasym Xl
10. Dexmethylphenidate Hydrochloride [usan]
11. Ritalin
12. 4b3sc438hi
13. Dex-methylphenidate Hydrochloride
14. Methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;hydrochloride
15. 1678ok0e08
16. Methylphenidate D-threo-form Hydrochloride
17. Methyl (2r)-phenyl((2r)-piperidin-2-yl)acetate Hydrochloride
18. 19262-68-1 (hcl)
19. Methyl (2r)-2-phenyl-2-[(2r)-piperidin-1-ium-2-yl]acetate;chloride
20. Quillichew
21. Quillivant
22. Aptensio
23. Foquest
24. Oros Mph
25. Aptensio Xr
26. Methylin Er
27. Ritalin La
28. Ritalin Sr
29. Chembl904
30. (r)-methyl 2-phenyl-2-((r)-piperidin-2-yl)acetate Hydrochloride
31. Daytrana
32. Dexmethylphenidate Hydrochloride (usan)
33. Spd544
34. Spd-544
35. Dl-threo-methylphenidate Hcl
36. Biphentin
37. Equasym
38. Methypatch
39. Metadate Mr
40. Unii-1678ok0e08
41. Equasym Ir
42. Ritalin Qd
43. Focalin (tn)
44. Dl-threo-methylphenidate Hydrochloride
45. Adhansia Xr
46. Jornay Pm
47. Methyl .alpha.-phenyl-2-piperidineacetate Hydrochloride
48. Unii-4b3sc438hi
49. Nwp-06
50. Dtxsid50940927
51. D-threo Methylphenidate Hydrochloride
52. Akos027321667
53. Rac-threo-methylphenidate Hydrochloride
54. 2-piperidineacetic Acid, Alpha-phenyl-, Methyl Ester, Hydrochloride, (alphar,2r)-
55. 2-piperidineacetic Acid, Alpha-phenyl-, Methyl Ester, Hydrochloride, (r*,r*)- (+-)-
56. 2-piperidineacetic Acid, Alpha-phenyl-, Methyl Ester, Hydrochloride, (r-(r*,r*))-
57. Methylphenidate Hydrochloride [mi]
58. (+/-)-threo-methylphenidate Hydrochloride
59. Methylphenidate Hydrochloride [jan]
60. Methylphenidate Hydrochloride [mart.]
61. Methylphenidate Hydrochloride [vandf]
62. Methylphenidate Hydrochloride [who-dd]
63. D03721
64. Dexmethylphenidate Hydrochloride [mart.]
65. Dexmethylphenidate Hydrochloride [vandf]
66. Dexmethylphenidate Hydrochloride [who-dd]
67. Methylphenidate Hydrochloride [orange Book]
68. Methylphenidate Hydrochloride Cii [usp-rs]
69. Methylphenidate Hydrochloride [ep Monograph]
70. Methylphenidate Hydrochloride [usp Monograph]
71. Dexmethylphenidate Hydrochloride [orange Book]
72. Methylphenidate D-threo-form Hydrochloride [mi]
73. Q47487562
74. Azstarys Component Dexmethylphenidate Hydrochloride
75. Dexmethylphenidate Hydrochloride Component Of Azstarys
76. Methyl Phenyl(piperidin-2-yl)acetate--hydrogen Chloride (1/1)
77. Methylphenidate Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
78. 2-piperidineacetic Acid, .alpha.-phenyl-, Methyl Ester, Hydrochloride, (r*,r*)-(+/-)-
79. 2-piperidineacetic Acid, .alpha.-phenyl-, Methyl Ester, Hydrochloride,(.alpha.r,2r)-
Molecular Weight | 269.77 g/mol |
---|---|
Molecular Formula | C14H20ClNO2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 4 |
Exact Mass | 269.1182566 g/mol |
Monoisotopic Mass | 269.1182566 g/mol |
Topological Polar Surface Area | 38.3 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 249 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Dexmethylphenidate hydrochloride |
Drug Label | Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threo-enantiomers. Focalin is a central nervous system (CNS) stimulant, available in 3 tabl... |
Active Ingredient | Dexmethylphenidate hydrochloride |
Dosage Form | Tablet; Capsule, extended release |
Route | oral; Oral |
Strength | 2.5mg; 5mg; 25mg; 30mg; 10mg; 15mg; 40mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Watson Labs; Mylan Pharms; Teva Pharms; Intellipharmaceutics; Teva Pharms Usa |
2 of 6 | |
---|---|
Drug Name | Focalin |
PubMed Health | Dexmethylphenidate (By mouth) |
Drug Classes | CNS Stimulant |
Drug Label | Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threo-enantiomers. Focalin is a central nervous system (CNS) stimulant, available in 3 tabl... |
Active Ingredient | Dexmethylphenidate hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 2.5mg; 5mg; 10mg |
Market Status | Prescription |
Company | Novartis |
3 of 6 | |
---|---|
Drug Name | Focalin xr |
PubMed Health | Dexmethylphenidate (By mouth) |
Drug Classes | CNS Stimulant |
Drug Label | Focalin XR is an extended-release formulation of dexmethylphenidate with a bi-modal release profile. Focalin XR uses the proprietary SODAS (Spheroidal Oral Drug Absorption System) technology. Each bead-filled Focalin XR capsule contains half the dose... |
Active Ingredient | Dexmethylphenidate hydrochloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 25mg; 30mg; 15mg; 5mg; 10mg; 40mg; 20mg; 35mg |
Market Status | Prescription |
Company | Novartis |
4 of 6 | |
---|---|
Drug Name | Dexmethylphenidate hydrochloride |
Drug Label | Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threo-enantiomers. Focalin is a central nervous system (CNS) stimulant, available in 3 tabl... |
Active Ingredient | Dexmethylphenidate hydrochloride |
Dosage Form | Tablet; Capsule, extended release |
Route | oral; Oral |
Strength | 2.5mg; 5mg; 25mg; 30mg; 10mg; 15mg; 40mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Watson Labs; Mylan Pharms; Teva Pharms; Intellipharmaceutics; Teva Pharms Usa |
5 of 6 | |
---|---|
Drug Name | Focalin |
PubMed Health | Dexmethylphenidate (By mouth) |
Drug Classes | CNS Stimulant |
Drug Label | Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threo-enantiomers. Focalin is a central nervous system (CNS) stimulant, available in 3 tabl... |
Active Ingredient | Dexmethylphenidate hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 2.5mg; 5mg; 10mg |
Market Status | Prescription |
Company | Novartis |
6 of 6 | |
---|---|
Drug Name | Focalin xr |
PubMed Health | Dexmethylphenidate (By mouth) |
Drug Classes | CNS Stimulant |
Drug Label | Focalin XR is an extended-release formulation of dexmethylphenidate with a bi-modal release profile. Focalin XR uses the proprietary SODAS (Spheroidal Oral Drug Absorption System) technology. Each bead-filled Focalin XR capsule contains half the dose... |
Active Ingredient | Dexmethylphenidate hydrochloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 25mg; 30mg; 15mg; 5mg; 10mg; 40mg; 20mg; 35mg |
Market Status | Prescription |
Company | Novartis |
Dopamine Uptake Inhibitors
Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)
Central Nervous System Stimulants
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
DEXMETHYLPHENIDATE HYDROCHLORIDE
Brand Name : DEXMETHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 5MG
Approval Date : 2020-09-09
Application Number : 213813
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
DEXMETHYLPHENIDATE HYDROCHLORIDE
Brand Name : DEXMETHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 10MG
Approval Date : 2020-09-09
Application Number : 213813
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
DEXMETHYLPHENIDATE HYDROCHLORIDE
Brand Name : DEXMETHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 15MG
Approval Date : 2020-09-09
Application Number : 213813
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
DEXMETHYLPHENIDATE HYDROCHLORIDE
Brand Name : DEXMETHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 20MG
Approval Date : 2020-09-09
Application Number : 213813
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
DEXMETHYLPHENIDATE HYDROCHLORIDE
Brand Name : DEXMETHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 25MG
Approval Date : 2020-09-09
Application Number : 213813
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
DEXMETHYLPHENIDATE HYDROCHLORIDE
Brand Name : DEXMETHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 30MG
Approval Date : 2020-09-09
Application Number : 213813
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
DEXMETHYLPHENIDATE HYDROCHLORIDE
Brand Name : DEXMETHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 35MG
Approval Date : 2020-09-09
Application Number : 213813
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
RLD : No
TE Code : AB
DEXMETHYLPHENIDATE HYDROCHLORIDE
Brand Name : DEXMETHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 40MG
Approval Date : 2020-09-09
Application Number : 213813
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
DEXMETHYLPHENIDATE HYDROCHLORIDE
Brand Name : DEXMETHYLPHENIDATE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 2.5MG
Approval Date : 2017-09-25
Application Number : 209468
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
DEXMETHYLPHENIDATE HYDROCHLORIDE
Brand Name : DEXMETHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 40MG
Approval Date : 2013-11-19
Application Number : 202731
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 393
2019 Revenue in Millions : 419
Growth (%) : -6
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 368
2020 Revenue in Millions : 393
Growth (%) : -6
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 282
2015 Revenue in Millions : 365
Growth (%) : -23
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 236
2016 Revenue in Millions : 282
Growth (%) : -16
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 463
2017 Revenue in Millions : 488
Growth (%) : -5%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 419
2018 Revenue in Millions : 463
Growth (%) : -10
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2037-12-09
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE
US Patent Number : 10759778
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212994
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-12-09
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2037-12-09
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE
US Patent Number : 10954213
Drug Substance Claim :
Drug Product Claim :
Application Number : 212994
Patent Use Code : U-3094
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-12-09
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2037-12-09
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE
US Patent Number : 10584113
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212994
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-12-09
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2037-12-09
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE
US Patent Number : 10858341
Drug Substance Claim :
Drug Product Claim :
Application Number : 212994
Patent Use Code : U-3094
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-12-09
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2032-07-27
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE
US Patent Number : 9079928
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212994
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-07-27
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2037-12-09
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE
US Patent Number : 10584112
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212994
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-12-09
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2037-12-09
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE
US Patent Number : 10759778
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212994
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-12-09
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2037-12-09
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE
US Patent Number : 10584112
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 212994
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-12-09
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2037-12-09
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE
US Patent Number : 10584113
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212994
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-12-09
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2037-12-09
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE
US Patent Number : 10584113
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212994
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-12-09
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2018-06-22
Date Granted : 2004-08-17
Brand Name : ATTENADE
Patent Number : 2241611
Filing Date : 1998-06-22
Strength per Unit : 10 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2018-06-22
Date Granted : 2004-08-17
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2018-06-11
Date Granted : 2004-12-28
Brand Name : ATTENADE
Patent Number : 2240329
Filing Date : 1998-06-11
Strength per Unit : 2.5 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2018-06-11
Date Granted : 2004-12-28
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2018-06-22
Date Granted : 2004-08-17
Brand Name : ATTENADE
Patent Number : 2241611
Filing Date : 1998-06-22
Strength per Unit : 2.5 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2018-06-22
Date Granted : 2004-08-17
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2018-06-11
Date Granted : 2004-12-28
Brand Name : ATTENADE
Patent Number : 2240329
Filing Date : 1998-06-11
Strength per Unit : 5 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2018-06-11
Date Granted : 2004-12-28
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2018-06-22
Date Granted : 2004-08-17
Brand Name : ATTENADE
Patent Number : 2241611
Filing Date : 1998-06-22
Strength per Unit : 5 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2018-06-22
Date Granted : 2004-08-17
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2018-06-11
Date Granted : 2004-12-28
Brand Name : ATTENADE
Patent Number : 2240329
Filing Date : 1998-06-11
Strength per Unit : 10 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2018-06-11
Date Granted : 2004-12-28
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
ABOUT THIS PAGE
49
PharmaCompass offers a list of Dexmethylphenidate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dexmethylphenidate manufacturer or Dexmethylphenidate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dexmethylphenidate manufacturer or Dexmethylphenidate supplier.
PharmaCompass also assists you with knowing the Dexmethylphenidate API Price utilized in the formulation of products. Dexmethylphenidate API Price is not always fixed or binding as the Dexmethylphenidate Price is obtained through a variety of data sources. The Dexmethylphenidate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A (+/-)-threo-Methylphenidate hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of (+/-)-threo-Methylphenidate hydrochloride, including repackagers and relabelers. The FDA regulates (+/-)-threo-Methylphenidate hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. (+/-)-threo-Methylphenidate hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of (+/-)-threo-Methylphenidate hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A (+/-)-threo-Methylphenidate hydrochloride supplier is an individual or a company that provides (+/-)-threo-Methylphenidate hydrochloride active pharmaceutical ingredient (API) or (+/-)-threo-Methylphenidate hydrochloride finished formulations upon request. The (+/-)-threo-Methylphenidate hydrochloride suppliers may include (+/-)-threo-Methylphenidate hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of (+/-)-threo-Methylphenidate hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A (+/-)-threo-Methylphenidate hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of (+/-)-threo-Methylphenidate hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of (+/-)-threo-Methylphenidate hydrochloride DMFs exist exist since differing nations have different regulations, such as (+/-)-threo-Methylphenidate hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A (+/-)-threo-Methylphenidate hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. (+/-)-threo-Methylphenidate hydrochloride USDMF includes data on (+/-)-threo-Methylphenidate hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The (+/-)-threo-Methylphenidate hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of (+/-)-threo-Methylphenidate hydrochloride suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing (+/-)-threo-Methylphenidate hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for (+/-)-threo-Methylphenidate hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture (+/-)-threo-Methylphenidate hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain (+/-)-threo-Methylphenidate hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a (+/-)-threo-Methylphenidate hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of (+/-)-threo-Methylphenidate hydrochloride suppliers with NDC on PharmaCompass.
(+/-)-threo-Methylphenidate hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of (+/-)-threo-Methylphenidate hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right (+/-)-threo-Methylphenidate hydrochloride GMP manufacturer or (+/-)-threo-Methylphenidate hydrochloride GMP API supplier for your needs.
A (+/-)-threo-Methylphenidate hydrochloride CoA (Certificate of Analysis) is a formal document that attests to (+/-)-threo-Methylphenidate hydrochloride's compliance with (+/-)-threo-Methylphenidate hydrochloride specifications and serves as a tool for batch-level quality control.
(+/-)-threo-Methylphenidate hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each (+/-)-threo-Methylphenidate hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
(+/-)-threo-Methylphenidate hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia ((+/-)-threo-Methylphenidate hydrochloride EP), (+/-)-threo-Methylphenidate hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia ((+/-)-threo-Methylphenidate hydrochloride USP).